Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Current Deferred Revenue: 2019-2023

  • CureVac N.V's Current Deferred Revenue rose 35.26% to $48.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $48.0 million, marking a year-over-year increase of 35.26%. This contributed to the annual value of $48.0 million for FY2023, which is 35.26% up from last year.
  • CureVac N.V's Current Deferred Revenue amounted to $48.0 million in Q4 2023, which was up 35.26% from $35.5 million recorded in Q4 2022.
  • Over the past 5 years, CureVac N.V's Current Deferred Revenue peaked at $188.4 million during Q4 2020, and registered a low of $8.3 million during Q4 2019.
  • Moreover, its 3-year median value for Current Deferred Revenue was $48.0 million (2023), whereas its average is $49.1 million.
  • Per our database at Business Quant, CureVac N.V's Current Deferred Revenue surged by 2,174.75% in 2020 and then crashed by 66.14% in 2021.
  • CureVac N.V's Current Deferred Revenue (Quarterly) stood at $8.3 million in 2019, then surged by 2,174.75% to $188.4 million in 2020, then tumbled by 66.14% to $63.8 million in 2021, then slumped by 44.40% to $35.5 million in 2022, then surged by 35.26% to $48.0 million in 2023.
  • Its Current Deferred Revenue was $48.0 million in Q4 2023, compared to $35.5 million in Q4 2022 and $63.8 million in Q4 2021.